See this page online at: http://www.bioscienceworld.ca/2004Issue9
Sign up for your free subscription and keep up-to-date.
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
|
September 20 2004
Gut Instincts By Deborah Komlos AXCAN PHARMA HAS GROWN TO CAPTURE A LARGE MARKET SHARE IN GI PHARMACEUTICALS
|
|
September 20 2004
FOR BETTER OR FOR WORSE . . . By Helen Paparis, B.Sc., MBA A REAL TO-DO LIST FOR MANAGING A CONTRACT MANUFACTURER FOR A BIOLOGIC PRODUCT
|
|
September 20 2004
The IPO window: who will follow MethylGene? By Patricia Nicholson The biotech industry turned its eyes to MethylGene Inc. (Montreal, QC), which completed a much-anticipated initial public offering in June.
|
|
September 20 2004
ASKED & ANSWERED Compiled by Amber Lepage-Monette Among the major developed countries, significant uncertainty characterizes Canadian patent law with respect to living organisms.
|
|
R & D News
|
|
Business Corner
|
|
Clinical Trials & Patents
|
|
Dealmakers
|